Print Page  Close Window    

Stemcells, Inc. Regains Compliance For Continued Nasdaq Global Market Listing

NEWARK, Calif., July 21, 2011 – StemCells, Inc. (NASDAQ: STEMD), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it has received notification from The NASDAQ Stock Market that the Company has regained compliance with the minimum bid price requirement.  In order to continue listing on the NASDAQ Global Market, the NASDAQ Listing Rules require the Company’s stock to evidence a closing bid price of $1.00 per share or more for ten consecutive days.  On July 20, 2011, the closing bid price of the Company’s common stock was $3.75 per share, the tenth consecutive day the bid price closed above $1.00 per share.

 

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders.  Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children.  In addition, the Company plans to file an IND by year-end 2011 to initiate a clinical trial of HuCNS-SC cells in a retinal disorder, such as age-related macular degeneration, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer’s disease and stroke.  StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.  

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein.  These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the timing and prospects associated with filing an IND to initiate a clinical trial in age-related macular degeneration; the Company’s ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Form 8-K.

CONTACT:       

Rodney Young
Chief Financial Officer
(510) 456-4128